Edition:
United States

Delcath Systems Inc (DCTH.O)

DCTH.O on Consolidated Issue listed on NASDAQ Capital Market

0.17USD
21 Feb 2017
Change (% chg)

$0.01 (+7.59%)
Prev Close
$0.16
Open
$0.21
Day's High
$0.24
Day's Low
$0.16
Volume
46,224,565
Avg. Vol
1,831,897
52-wk High
$6.85
52-wk Low
$0.13

DCTH.O

Chart for DCTH.O

About

Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System... (more)

Overall

Beta: 1.60
Market Cap(Mil.): $0.35
Shares Outstanding(Mil.): 2.20
Dividend: --
Yield (%): --

Financials

  DCTH.O Industry Sector
P/E (TTM): -- 34.21 29.32
EPS (TTM): -10.07 -- --
ROI: -112.21 12.42 13.03
ROE: -161.99 14.41 14.17

BRIEF-Empery Asset Management LP dissolves passive stake in Delcath Systems

* Empery Asset Management LP dissolves passive stake in Delcath Systems Inc as of Dec 30, 2016 - SEC filing

Jan 31 2017

BRIEF-Delcath announces patient treatment in intrahepatic Cholangiocarcinoma study

* Delcath Systems Inc - patient treatment, data collection for intrahepatic cholangiocarcinoma (ICC) cohort of European Phase 2 HCC/ICC study is ongoing

Jan 12 2017

BRIEF-Delcath Q3 loss $0.66/shr

* Believes it has sufficient capital to fund its operating activities through end of 2017

Nov 11 2016

BRIEF-Delcath Systems issues letter to stockholders

* Assuming conditions are satisfied, expect anticipated qtrly releases throughout 2017 will fund clinical development plan through 2017-end Source text for Eikon: Further company coverage:

Oct 18 2016

BRIEF-Delcath Systems announces new clinical sites for FOCUS Phase 3 trial for ocular melanoma liver metastases

* Delcath Systems - 5 new clinical trial sites in U.S. have been activated in global FOCUS Phase 3 clinical trial for ocular melanoma liver metastases

Oct 11 2016

BRIEF-Delcath prices underwritten public offering at $3.00 per share

* Delcath prices underwritten public offering of common stock and warrants

Sep 30 2016

BRIEF-Delcath announces proposed public offering of common stock and warrants

* Delcath announces proposed public offering of common stock and warrants

Sep 29 2016

More From Around the Web

Earnings vs. Estimates